On Apr. 2, 2020, BioAegis Therapeutics announced that it was preparing to evaluate plasma gelsolin replacement in severe infection, specifically severe community-acquired pneumonia (sCAP), including COVID-19, and have engaged leading infectious disease experts to advise the proof of concept clinical trial strategy.

The intellectual property technology was licensed from Harvard Medical School.